Release Date: August 2007

Valid Through: August 2008

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM



Fee: There is no fee for this activity

This CME activity is based on the following:

Myelosuppression: A Report from MASCC 2007 
Jeffrey Crawford, MD, Professor of Medicine, Duke University Medical Center

Update on the Management of Mucositis: MASCC 2007 
Stephen T. Sonis, DMD, DMSc, Professor and Chair, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine

Jeffrey Crawford, MD

Dr. Crawford is Chief of Medical Oncology at Duke University Medical Center and Associate Director of Clinical Research at the Duke Comprehensive Cancer Center. Dr. Crawford has led many investigations of U.S. trials of cancer drugs, several of which led to FDA approval, with a focus on new agents in lung cancer and hematopoietic growth factors. He is editor-in-chief of Cancer Supportive Therapy and serves on several editorial boards of other cancer journals. Dr. Crawford earned his bachelor’s degree at Ohio Wesleyan University and his medical degree at Ohio State University. He was an intern, junior assistant resident and senior assistant resident at Duke from 1974-77, and hematology/oncology fellow at Duke from 1977-81. In 1978-79, Dr. Crawford was chief resident in medicine at Duke University/Veteran’s Administration Medical Center, and later a geriatric fellow from 1979-82. In 2003, Duke honored Dr. Crawford with the Joseph Greenfield Research Faculty Award. This was on the heels of the Wayne Rundles Award for Excellence in Clinical Research that Duke bestowed upon him in 2002 and the Wendell Rosse Teaching Award in 2000. In 2003, he earned membership in Alpha Omega Alpha. He currently holds several position s with the National Comprehensive Cancer Network, including chair of the Myeloid Growth Factor Committee and member of both the Clinical Trials Network Investigator Steering Committee and the Small Cell Lung Cancer Guidelines Committee. He also chairs committees for the American Society of Clinical Oncology and the Multinational Association of Supportive Care. Dr. Crawford has served as principal investigator for Cancer and Leukemia Group B clinical trials at Duke for more than a decade and is vice chair of the CALGB respiratory committee. In 2005, he was awarded the George Barth Geller, MD Professor for Research in Cancer.

Steven Sonis, DMD, DMSc

Dr. Sonis is the Chief of the Division of Oral Medicine at the Dana-Farber Cancer Institute; Senior Surgeon at Brigham and Women’s Hospital; and Professor of Oral Medicine at the Harvard School of Dental Medicine. He has published extensively on the clinical, biological, and health economic aspects of oral complications of cancer therapy. He is the author of more than 125 original publications, 40 reviews and chapters, and 7 books. He has lectured extensively on the clinical and biological aspects of mucosal barrier injury induced by cancer therapy. Dr. Sonis serves on a number of editorial boards, and is a founding member of the International Society of Oral Oncology.  

Learning Objectives

Upon completion of this activity, participants should be able to:

• Evaluate clinical trial data presented at ASCO based on study design, the reported results, and authors’ conclusions.
• Consider the reviewed data as it relates to previous, concurrent and future treatment of renal cell carcinoma.
• Consider the rationale for the use of current and emerging therapies in single agent and in combination modalities for renal cell carcinoma
• Evaluate the current and emerging data for earlier lines of therapy, and various administration methods with respect to overall patient outcomes, safety, and efficacies.
  
  

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters

This activity is supported by an educational donation provided by Amgen.